Combined ICI in patients with NSCLC and PD-L1 ≥50% also probably lead to a higher OS rate (HR 0.72, 95% CI [0.59–0.89]), but its effect on PFS, ORR, and HRQoL is unknown due to a lack of data. This evidence concerns the gene CD274 and non-small cell lung carcinoma.